Implanet Reports Q1 2021 Revenue of €1.7 Million, Driven by the Dramatic Growth of Its Spine Activity
20 Avril 2021 - 08:00AM
Business Wire
- Global revenue growth: +7%, driven by +13% increase in
direct sales
- Growth in JAZZ® Spine activity: +41%
A webinar will be held at 6 pm (Paris time)
today, April 20, 2021:
https://us02web.zoom.us/webinar/register/WN_xRVpxI-iRIOkUdiWTPU8iA
Regulatory News:
IMPLANET (Paris:ALIMP) (Euronext Growth: ALIMP, FR0013470168,
éligible PEA-PME), eligible for PEA-PME equity savings plans), a
medical technology company specializing in vertebral and
knee-surgery implants, today announced its revenue for the first
quarter of 2021.
Revenue (€ thousands - IFRS*)
Q1 2021
Q1 2020
Change
Spine (JAZZ®)
1,026
728
+41%
Knee
653
839
-22%
Total revenue
1,678
1,567
+7%
*Unaudited data
Implanet CEO Ludovic Lastennet said: “The first few
months of 2021 were marked by solid sales momentum. Despite the
public health situation, which has slowed surgical activity
globally, we posted total growth of +7% with an excellent
performance with JAZZ®, which increased by 41% over the period,
again reflecting the adoption of our technology by surgeons and the
clinical appeal of our products for patients. At the same time, we
have reached a new structural milestone with the finalization of
the project to acquire Orthopaedic & Spine Development, which
also recorded growth in its activity during the first three months
of this year. This new ensemble’s objective will be to position
ourselves as a benchmark player in orthopedic surgery in France,
and it will only strengthen the sales momentum we are currently
generating”.
In the first quarter of 2021, Implanet posted revenue of €1.68
million, up 7% (vs. €1.57 million in Q1 2020). JAZZ® sales totaled
€1.03 million (vs. €0.73 million in Q1 2020), while Knee activity
fell 22% to €0.65 million, impacted by a very sharp slowdown in
activity in Brazil associated with the extent of the health crisis
in that country.
JAZZ® sales recorded substantial growth in countries in which
the Company operates directly, notably in the United States, where
sales totaled €0.42 million (+64%) thanks to the sale of 313 units
(+71%), and in France, which generated sales of €0.35 million (+19%
in value terms), i.e. a total volume of 968 units sold (+21%).
Export activity also generated buoyant growth, +45%, with sales
totaling €0.26 million (vs. €0.18 million).
All in all during the first quarter of 2021, Implanet sold 1,952
JAZZ® units, an increase of +29% over Q1 2020.
Knee activity remained relatively stable in France at €0.64
million (vs. €0.68 million in 2020), despite the various waves of
lockdown over the period. The impact on overseas activity was more
substantial, primarily in Brazil.
Lastly, Implanet would like to remind readers that the
acquisition of Orthopaedic & Spine Development (“OSD”) is
subject to the approval of its shareholders at the General Meeting
of May 5, 2021. OSD recorded unaudited revenue of €1.02 million in
the first quarter of 2021, up 7% (vs. €0.95 million). The Group’s
pro forma revenue for the quarter would thus have been €2.69
million.
Q1 2021 highlights
- Commercial launch of the JAZZ® PF implant, which has already
received 510 (k) clearance from the FDA and CE marking in
Europe;
- Clearance of the MADISONTM total knee prosthesis by the
Therapeutic Goods Administration (TGA) for marketing in
Australia;
- Finalization of the agreement to acquire OSD, which specializes
in developing, manufacturing and marketing implants for spine
surgery. This agreement is subject to shareholder approval at the
General Meeting of May 5, 2021.
A webinar will be held at 6 pm CEST today, April 20,
2021
The Company would like to inform its shareholders that a webinar
will be held at 6 pm today.
During this web conference, Chief Executive Officer Ludovic
Lastennet and Chief Financial Officer David Dieumegard will present
Implanet’s strategic focuses following the finalization of the
agreement to acquire OSD. The webinar will be held in French and
will be followed by a Q&A session.
To follow this webinar, just log in via the following link:
https://us02web.zoom.us/webinar/register/WN_xRVpxI-iRIOkUdiWTPU8iA
Upcoming financial events:
- H1 2021 revenue, July 6, 2021 after market - H1 2021
results, September 21, 2021 after market
About Implanet
Founded in 2007, Implanet is a medical technology company that
manufactures high-quality implants for orthopedic surgery. Its
activity revolves around two product ranges, the latest generation
JAZZ® implant, designed to improve the treatment of spinal
pathologies requiring vertebral fusion surgery, and the MADISON
implant designed for first-line prosthetic knee surgery. Implanet’s
tried-and-tested orthopedic platform is based on product
traceability. Protected by four families of international patents,
JAZZ® and MADISON have obtained 510(k) regulatory clearance from
the Food and Drug Administration (FDA) in the United States, the CE
mark as well as the ANVISA authorization in Brazil. Implanet
employs 29 staff and recorded 2020 sales of €6.0 million. For
further information, please visit www.implanet.com. Based near
Bordeaux in France, Implanet established a US subsidiary in Boston
in 2013. Implanet is listed on Euronext™ Growth market in
Paris.
The Company would like to remind that the table for monitoring
the equity line (OCA, OCAPI, BSA) and the number of shares
outstanding, is available on its website:
http://www.implanet-invest.com/suivi-des-actions-80
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210419005437/en/
IMPLANET Ludovic Lastennet, CEO David Dieumegard, CFO
Tel.: +33 (0)5 57 99 55 55 investors@Implanet.com
NewCap Investor Relations Mathilde Bohin
Nicolas Fossiez Tel.: +33 (0)1 44 71 94 94
Implanet@newcap.eu
NewCap Media Relations Nicolas Merigeau
Tel.: +33 (0)1 44 71 94 94 Implanet@newcap.eu
Implanet (EU:ALIMP)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Implanet (EU:ALIMP)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024